Antibody Responses to Influenza Virus Vaccine in Patients With Acute Lymphocytic Leukaemia

Abstract

Feery, B. J., Matthews, R. N., Evered, M. G., and Gallichio, H. A. (1979). Aust. Paediatr. J., 15, 177–180. Antibody responses to influenza virus vaccine in children with acute lymphocytic leukaemia. Antibody responses to influenza immunization in children with acute lymphocytic leukaemia in remission were studied in two successive years. Initial antibody levels, the response to immunization, and final antibody levels were lower than in a group of children with cystic fibrosis. The results indicate that both primary and anamnestic antibody responses are depressed in children with acute leukaemia when they are on immunosuppressive therapy. Despite this depression the majority of the patients reached protective antibody levels to the A/Victoria/3/75 and A/Texas/1/77 (H3N2) antigens but not to the recent A/USSR/90/77 (H1N1) antigens.

Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy

“…Vaccinations (H1N1A, H3N2A, B, and pandemic H1N1Swl) produced no significant adverse events, but resulted in limited seroresponse rates (22%, 37%, 22%, and 30%, respectively). These results were similar to response rates reported earlier for influenza viruses , and recently for pandemic influenza virus A .…”

“…There is conflicting data regarding the effectiveness of seasonal influenza immunization in children during chemotherapy . Randomized controlled trials (RCTs), and controlled clinical trials (CCTs), in which the serologic response to influenza vaccination of children with cancer was compared to other control groups, were analyzed in 2009.…”

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer

“…The studies have been conducted over a large chronological time span, thus variations in susceptibility, differing circulating influenza strains, and vaccine composition need to be considered. Our study is only the second performed in the Southern Hemisphere using Southern Hemisphere influenza vaccine formulation, with the other study undertaken more than 30 years ago .…”

“…Our study confirms that immunocompromised children receiving treatment for cancer are able to mount a clinically significant immune response to the trivalent inactivated influenza vaccine. A wide range for seroprotection and seroconversion following administration of the trivalent influenza vaccine has been reported in this setting (summarized in Table 4) [24][25][26][27][28][29][30][31][32][33][34][35]. In our cohort, immunogenicity was toward the middle of these ranges: seroprotection H3N2 55% (range from published literature: 25-92%), H1N1 61% (5-96%), and B 41% (15-87%); seroconversion H3N2 43% (25-78%), H1N1 43% (16-84%), and B 33% (12-60%).…”

Vaccination of the immunocompromised host

“…Generell ist die Impfantwort bei Patienten mit Malignomen im Vergleich zu gesunden Personen vermindert [31][32][33][34][35][36][37][38][39][40][41][42][43]. Generell ist die Impfantwort bei Patienten mit Malignomen im Vergleich zu gesunden Personen vermindert [31][32][33][34][35][36][37][38][39][40][41][42][43].…”